Global call launched to tackle retinal drug delivery challenges

BioMed X and Boehringer Ingelheim are expanding their joint XSeed Labs incubator in Ridgefield, Connecticut, with the launch of a second research group focused on next-generation intraocular biologics.

The new initiative aims to address the need for longer-lasting treatments for retinal diseases - specifically reducing the burden of frequent intraocular injections. A global call for proposals invites researchers to develop novel biologic platforms that combine extended intraocular activity with deep retinal penetration.

The selected team will work independently on-site to explore new design principles, develop a high-throughput human in vitro model for screening candidate biologics, and validate the most promising leads in preclinical models.

“Our goal is to push the boundaries of biologics design in ophthalmology,” said Mark Johnston, CEO of BioMed X USA. “This collaboration brings academic creativity into direct alignment with pharmaceutical innovation.”

The call is open to early-career researchers with expertise in ophthalmology, tissue engineering, or antibody discovery. Proposals must be submitted by 12 July 2025, via the BioMed X Career Space. 

More information online